Abiraterone Acetate API Market
Abiraterone Acetate API Market Scope: Industry
Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Abiraterone Acetate API Market Size and Growth
The Abiraterone Acetate API market is experiencing robust growth, driven by rising prostate cancer incidences and increased research funding. The market size is projected to reach approximately $500 million by 2025, reflecting significant demand for innovative therapies. Key trends include advancements in formulation and strategic collaborations among pharmaceutical companies.
Companies Covered
(Covid 19 Impact Covered)
◍ Cipla
◍ Tapi Teva
◍ HETERO
◍ Sterling S.P.A. IT
◍ Farmhispania Group
◍ Scion Pharm Taiwan
◍ Qilu Pharmaceutial
◍ Aurisco Pharmaceutical
◍ Aspen Bio Pharma Labs
◍ Shilpa Medicare Limited
◍ Shandong Chuangxin Pharmaceutical
Research and Development
◍ Zhejiang Xianju Junye Pharmaceutical
The Abiraterone Acetate API market features companies like Cipla, Teva, and HETERO, which manufacture and supply the API globally. These firms enhance market growth through innovation, cost-effective production, and expanding distribution channels. Some revenue figures include:
- Cipla: $2 billion
- Teva: $16.5 billion
- HETERO: $1 billion
◍ Wuhan Sunrise Technology Development
Request Sample Report
Market Segmentation
By Application
◍ Abiraterone Acetate Tablets
◍ Abiraterone Acetate Capsules
◍ Others
By Product
◍ Purity ≥ 98 % ◍ Purity ≥ 99 %
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
